Group 1 - Harbin Air Conditioning plans to transfer 40% equity of its subsidiary, Harbin Fushanchuan Biotechnology Development Co., Ltd. The subsidiary reported a net profit of -16.0963 million yuan for 2024, which is 218.83% of the previous year's net profit absolute value [1] - Xinhua Insurance expects a net profit of 29.986 billion to 34.122 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 45% to 65% [1][2] - Gansu Energy anticipates a net profit of 1.55 billion to 1.6 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 11.86% to 15.47% [2][3] Group 2 - Dongfang Tower forecasts a net profit of 750 million to 900 million yuan for the first three quarters of 2025, indicating a year-on-year growth of 60.83% to 93% [4] - Meili Eco announced that its subsidiary won a bid for an EPC project worth 2.375 billion yuan [6] - Bohai Chemical's wholly-owned subsidiary will undergo routine maintenance for its 600,000 tons/year PDH unit, expected to last about 30 days [8] Group 3 - Qin Port Co. reported a total throughput of 317.02 million tons for the first nine months of 2025, a year-on-year increase of 5.56% [10] - Jianglong Shipbuilding won a bid for a 72.99 million yuan fishery enforcement vessel project, accounting for 4.22% of its 2024 audited revenue [11] - Longyuan Technology expects a net profit of 35 million to 40 million yuan for the first three quarters of 2025, representing a year-on-year increase of 50.11% to 71.55% [12] Group 4 - Naipu Mining anticipates a net profit of 61 million to 66 million yuan for the first three quarters of 2025, reflecting a year-on-year decline of 45.16% to 49.32% [14] - Jinggong Steel Structure reported a cumulative contract amount of 17.98 billion yuan for the first nine months of 2025, a year-on-year increase of 4.8% [15][16] - Shenzhen Gas reported a net profit of 918 million yuan for the first three quarters of 2025, a year-on-year decrease of 13.08% [17] Group 5 - Yabao Pharmaceutical's subsidiary received a drug registration certificate for a new diabetes medication [18] - Shaanxi Coal's coal production in September was 14.56 million tons, a year-on-year increase of 5.34% [20] - Sifang New Materials reported a 15.94% year-on-year decline in concrete production for the first three quarters [22] Group 6 - Nanjing Foods reported a consolidated revenue of 276 million yuan in September, a slight increase of 0.0016% year-on-year [23] - Pulaike received a new veterinary drug registration certificate for a flea and tick treatment [24] - Zhucheng Technology received a cash dividend of 15 million yuan from its subsidiary [25] Group 7 - David Medical's subsidiary received a medical device registration certificate for a portable electronic endoscope image processor [26] - Zhongtong Bus reported a 36.88% year-on-year increase in sales in September, totaling 1,106 units [27] - Xiantan Co. reported a 11.95% year-on-year increase in chicken sales revenue in September [28] Group 8 - Bojun Technology expects a net profit of 552 million to 662 million yuan for the first three quarters of 2025, a year-on-year increase of 50% to 80% [30] - Haishi Pharmaceutical's innovative pain relief drug clinical trial application has been accepted [31] - Lingxiao Pump Industry used 80 million yuan of idle funds to purchase financial products [32] Group 9 - Qiangda Circuit's subsidiary completed business registration changes to expand its operational scope [33] - *ST Tianyu's controlling shareholder applied for bankruptcy liquidation due to severe financial difficulties [34] - Baolidi's shareholder plans to reduce holdings by up to 1 million shares [36] Group 10 - Zijin Mining completed the acquisition of Kazakhstan's Raygorodok gold mine, controlling 100% of its rights [44] - Zhonggang Luoyang's indirect controlling shareholder completed a capital increase, raising registered capital from approximately 26.666 billion yuan to 44.824 billion yuan [46] - Jinyu Jidong's director resigned due to work adjustments [47]

HSK45019是公司自主研究，具有独立知识产权的小分子抑制剂，HSK45019有望为炎症性肠病患者提供 一种新颖的治疗方法，带来更便捷和有效的治疗选择。根据国家药品监督管理局关于发布《化学药品注 册分类及申报资料要求》的通告(2020年第44号)中化学药品注册分类的规定，本品属于化学药品1类。 海思科（002653）(002653.SZ)发布公告，公司子公司上海海思盛诺医药科技有限公司于近日收到国家 药品监督管理局下发的《受理通知书》，涉及药品："HSK45019片"。 ...

Core Viewpoint - The announcement indicates that the company’s subsidiary, Shanghai Hisun Shennuo Pharmaceutical Technology Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for the drug "HSK45019 tablets," which is a novel treatment option for inflammatory bowel disease patients [1]. Group 1 - The drug HSK45019 is a small molecule inhibitor developed independently by the company and possesses independent intellectual property rights [1]. - HSK45019 is expected to provide a new and effective treatment option for patients suffering from inflammatory bowel disease, enhancing convenience and efficacy in treatment [1]. - According to the National Medical Products Administration's announcement regarding the classification of chemical drug registration, HSK45019 falls under Class 1 chemical drugs [1].

格隆汇10月13日丨海思科(002653.SZ)公布，子公司上海海思盛诺医药科技有限公司于近日收到国家药 品监督管理局下发的《受理通知书》，药品名称：HSK45019片。HSK45019是公司自主研究，具有独立 知识产权的小分子抑制剂，HSK45019有望为炎症性肠病患者提供一种新颖的治疗方法，带来更便捷和 有效的治疗选择。 ...

格隆汇10月13日丨海思科(002653.SZ)公布，子公司上海海思盛诺医药科技有限公司于近日收到国家药 品监督管理局下发的《受理通知书》，药品名称：HSK55718。HSK55718是公司自主研究的具有独立知 识产权的小分子非阿片类创新镇痛药物，有望在满足患者疼痛控制的同时，减少不良反应的发生并且避 免成瘾风险，为急性疼痛患者带来更加安全有效的镇痛选择。 ...

海思科（002653）(002653.SZ)发布公告，公司子公司上海海思盛诺医药科技有限公司于近日收到国家 药品监督管理局下发的《受理通知书》，涉及药品："HSK55718"。 HSK55718是公司自主研究的具有独立知识产权的小分子非阿片类创新镇痛药物，有望在满足患者疼痛 控制的同时，减少不良反应的发生并且避免成瘾风险，为急性疼痛患者带来更加安全有效的镇痛选择。 根据国家药品监督管理局关于发布《化学药品注册分类及申报资料要求》的通告(2020年第44号)中化学 药品注册分类的规定，本品属于化学药品1类。 ...

智通财经APP讯，海思科(002653.SZ)发布公告，公司子公司上海海思盛诺医药科技有限公司于近日收到 国家药品监督管理局下发的《受理通知书》，涉及药品："HSK55718"。 HSK55718是公司自主研究的具有独立知识产权的小分子非阿片类创新镇痛药物，有望在满足患者疼痛 控制的同时，减少不良反应的发生并且避免成瘾风险，为急性疼痛患者带来更加安全有效的镇痛选择。 根据国家药品监督管理局关于发布《化学药品注册分类及申报资料要求》的通告(2020年第44号)中化学 药品注册分类的规定，本品属于化学药品1类。 ...

格隆汇10月13日丨海思科(002653.SZ)公布，子公司上海海思盛诺医药科技有限公司于近日收到国家药 品监督管理局下发的《受理通知书》，药品名称：HSK50042片。HSK50042片是公司自主研发的口服、 强效、高选择性小分子抑制剂药物，拟用于呼吸系统疾病的治疗。 ...

临床前研究表明，HSK50042在较低剂量下即可有效改善模型小鼠的肺部疾病病理症状，具有良好的药 效作用，同时也表现出了良好的耐受性和较大的安全窗，是一款极具开发潜力的药物，有望为呼吸疾病 患者提供一种高效、安全的新型治疗选择。 海思科（002653）(002653.SZ)发布公告，公司子公司上海海思盛诺医药科技有限公司于近日收到国家 药品监督管理局下发的《受理通知书》，涉及药品：HSK50042片。HSK50042片是公司自主研发的口 服、强效、高选择性小分子抑制剂药物，拟用于呼吸系统疾病的治疗。 ...

目前HSK39297片在原发性IgA肾病患者中开展Ⅱ期临床研究中并完成了12周的核心治疗期，临床结果 显示达到预设终点。HSK39297片连续治疗12周能够较安慰剂组显著降低尿蛋白水平，整体安全性和耐 受性良好，为其纳入突破性治疗品种及进入Ⅲ期关键性临床研究阶段奠定了坚实的基础。 与此同时，公司正在推进HSK39297片针对阵发性睡眠性血红蛋白尿症的Ⅲ期临床研究。 HSK39297是公司自主研发的一种口服、强效和高选择性的补体因子B小分子抑制剂。临床拟用于治疗 补体参与介导的溶血性疾病及补体参与介导的原发性或继发性肾小球疾病等。 智通财经APP讯， 海思科(002653.SZ)发布公告，公司于2025年10月13日获悉，HSK39297片正式被国家 药品监督管理局药品审评中心(CDE)纳入《突破性治疗品种名单》，将极大的推动该领域新药的研发历 程，为我国肾脏/泌尿系统疾病的治疗带来新的希望。 ...